Trial reportMolecular psychiatry2021
Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials.
Trial report in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Dynamics of depression symptoms in adolescents during three types of psychotherapy and post-treatment follow-up.Journal of child psychology and psychiatry, and allied disciplines · 2025Trial
- Susceptibility mechanisms for analyzing depressive symptoms in differently disadvantaged children from an integrative perspective: a network analysis and network comparison.Translational psychiatry · 2025Article
- The effect of sertraline on networks of mood and anxiety symptoms: secondary analysis of the PANDA randomized controlled trial.Nature. Mental health · 2025Article
- Gender Difference in the Onset of Adolescent Depressive Symptoms: A Cross-Lagged Panel Network Analysis.Research on child and adolescent psychopathology · 2025Article
- How Coparenting Is Linked to Depression among Chinese Young Girls and Boys: Evidence from a Network Analysis.Behavioral sciences (Basel, Switzerland) · 2024Article
- Relations among symptoms of depression over time in at-risk youth.Journal of psychopathology and clinical science · 2023Article
- Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance.Psychological medicine · 2023Review
- Two distinct subtypes of obsessive compulsive disorder revealed by a framework integrating multimodal neuroimaging information.Human brain mapping · 2022Article
- Depressive symptom complexes of community-dwelling older adults: a latent network model.Molecular psychiatry · 2022Article
- Risk factors for suicidal behaviour in late-life depression: A systematic review.World journal of psychiatry · 2022Article
- A Narrative Review of Network Studies in Depression: What Different Methodological Approaches Tell Us About Depression.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression can be viewed as a network of depressive symptoms that tend to reinforce each other via feedback loops. Specific symptoms of depression may be differently responsive to antidepressant treatment, and some symptoms may be more important than others in the overall improvement of depression associated with treatment. We pooled prospective data from eight industry-sponsored placebo-controlled trials for paroxetine, fluoxetine and imipramine (total n = 3559) to examine whether improvements in specific depressive symptoms were more strongly related to improvements in other depressive symptoms among patients on active antidepressant treatment as compared to placebo. Depressive symptoms were assessed with the 17-item Hamilton Depression Rating Scale. Data on treatment was dichotomized into active treatment (receiving any antidepressant agent) vs. placebo. Time-lagged longitudinal analyses suggested that improvement in three symptoms-depressed mood, insomnia, and suicidality-had a broader overall impact on subsequent improvement in other depressive symptoms in the antidepressant condition compared to placebo (i.e., greater out-strength). Moreover, improvements in depressed mood and insomnia were more likely to follow the improvements in other symptoms in the antidepressant condition compared to placebo (i.e., greater in-strength). These results from clinical trial data suggest that depressed mood, insomnia, and suicidality may be particularly important in accounting for the remission and recovery in response to antidepressant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.